Replimune and Incyte to Collaborate on Clinical Trial Effort in Cutaneous Squamous Cell Carcinoma

 Initial study in the neoadjuvant setting designed to assess RP1 in combination with the small molecule, oral PD-L1 inhibitor, INCB99280

 

 Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor.

https://www.biospace.com/article/releases/replimune-and-incyte-enter-into-clinical-trial-collaboration-and-supply-agreement-to-evaluate-rp1-and-incb99280-in-patients-with-cutaneous-squamous-cell-carcinoma/